Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TESTOSTERONE CYPIONATE vs ANDROID 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Male hypogonadism (primary or hypogonadotropic),Delayed puberty in males,Off-label: Female-to-male gender affirmation therapy, anemia of renal failure (historically)
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
Approximately 8 days (terminal elimination half-life of testosterone cypionate after intramuscular injection; due to slow release from oil depot, effective half-life in muscle is ~8 days with a longer terminal phase up to 3 weeks)
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Primarily hepatic via CYP3A4 and CYP2B6; metabolites include androsterone and etiocholanolone; excreted in urine.
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Renal (90% as glucuronide and sulfate conjugates), fecal (10%)
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
97-99% bound to sex hormone-binding globulin (SHBG) and albumin
98% bound to sex hormone-binding globulin (SHBG) and albumin.
Approximately 0.6-1.0 L/kg (reflects extensive distribution into tissues, including muscle and fat; total Vd ~4-9 L in adults)
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
Intramuscular: 100% (administered as a depot injection in oil; undergoes first-pass metabolism if oral, but not relevant for IM route)
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
No specific dose adjustment recommended; however, monitor fluid retention and hypertension in patients with severe renal impairment (GFR <30 m L/min).
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
Child-Pugh A/B: No adjustment; Child-Pugh C: Contraindicated due to risk of hepatotoxicity.
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
Not recommended for use in pediatric patients for hypogonadism; for delayed puberty, IM testosterone cypionate 50 mg every 4 weeks initially, titrating upward as needed.
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
Start at lower end of dosing range (e.g., 50-100 mg every 2-4 weeks) due to increased risk of prostate enlargement and cardiovascular events; monitor serum testosterone levels and adjust accordingly.
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
Prolonged use of high doses of testosterone has been associated with an increased risk of hepatocellular carcinoma.
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
Risk of polycythemia (monitor hematocrit), edema in patients with cardiac/renal/hepatic disease, accelerated growth in prepubertal males (monitor bone age), gynecomastia, sleep apnea exacerbation, prostate hyperplasia/carcinoma (monitor PSA), decreased spermatogenesis, elevated blood pressure, hyperlipidemia.
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Known or suspected prostate carcinoma, male breast carcinoma, pregnancy, hypersensitivity to testosterone cypionate, severe hepatic/renal/cardiac disease (relative), hypercalcemia (in patients with immobility).
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
No significant food interactions. Limit alcohol consumption as it may increase risk of liver damage. Grapefruit juice may interfere with testosterone metabolism; avoid excessive intake.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
Testosterone cypionate is contraindicated in pregnancy. Androgenic effects may cause virilization of female fetus if exposed during organogenesis (first trimester). Second and third trimester exposure can also cause virilization. No adequate studies exist; use only if clearly needed for maternal condition, though use in pregnancy is generally avoided.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
Testosterone is excreted into breast milk in low concentrations; M/P ratio not reported. Theoretical risk of androgenic effects in male infants (e.g., masculinization). Use with caution only if maternal benefit outweighs potential risk. Consider alternative therapies while breastfeeding.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
No specific dose adjustment studies exist. Pharmacokinetic changes during pregnancy (increased clearance, volume of distribution) may reduce efficacy, but use of testosterone cypionate during pregnancy is contraindicated. If essential, dose may need titration to maintain desired androgen levels; however, risk outweighs benefit.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
Testosterone cypionate is a long-acting injectable androgen. Monitor hematocrit and hemoglobin due to risk of polycythemia. Use with caution in patients with sleep apnea, benign prostatic hyperplasia, or cardiovascular disease. Check serum testosterone levels 1 week after injection to assess adequacy. For men with hypogonadism, avoid in those with untreated hyperprolactinemia or pituitary tumor.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
Inject deeply into the muscle (gluteal or thigh) to reduce pain and risk of abscess.,Do not use if you have breast cancer, prostate cancer, or are pregnant.,Report swelling in ankles, difficulty breathing, or severe headache immediately.,Do not take with blood thinners like warfarin without consulting your doctor.,Expect possible mood changes, increased acne, or hair loss. Monitor for priapism.,Regular blood tests are required to check red blood cell count, liver function, and prostate health.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
"Chlorpropamide, a sulfonylurea antidiabetic agent, stimulates pancreatic insulin secretion, while testosterone may enhance insulin sensitivity and reduce blood glucose levels. Concurrent use can lead to additive hypoglycemic effects, increasing the risk of hypoglycemia, particularly in patients with diabetes. This interaction is of clinical concern as it may necessitate dose adjustments of chlorpropamide to prevent hypoglycemic episodes."
"Flunisolide, a corticosteroid with mineralocorticoid activity, can potentiate the sodium- and water-retaining effects of testosterone, leading to an increased risk of edema, hypertension, and exacerbation of heart failure. This interaction is particularly significant in patients with pre-existing cardiovascular conditions, as the combined effects on fluid balance may require dose adjustments or closer monitoring."
"Fluorometholone, a corticosteroid with mineralocorticoid activity, may enhance sodium and water retention induced by testosterone, particularly in patients with pre-existing cardiac or renal conditions. This interaction can lead to increased fluid retention, exacerbation of hypertension, and potential precipitation of congestive heart failure. The risk is greater with high doses or prolonged use of either agent."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TESTOSTERONE CYPIONATE vs ANDROID 5, answered by our medical review team.
TESTOSTERONE CYPIONATE is a Androgen that works by Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.. ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TESTOSTERONE CYPIONATE and ANDROID 5 depend on the specific clinical indication. These are both Androgen agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TESTOSTERONE CYPIONATE is: Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.. The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TESTOSTERONE CYPIONATE and ANDROID 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TESTOSTERONE CYPIONATE is classified as Category D/X. Testosterone cypionate is contraindicated in pregnancy. Androgenic effects may cause virilization of female fetus if exposed during organogenesis (first trimester). Second and thir. ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.